Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 124Breast Neoplasms 83Neoplasms 79Colorectal Neoplasms 66Neoplasm Metastasis 65Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 56Ovarian Neoplasms 56Pancreatic Neoplasms 53Multiple Myeloma 51Melanoma 39Triple Negative Breast Neoplasms 37Glioblastoma 36Lung Neoplasms 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Endometrial Neoplasms 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Carcinoma, Renal Cell 29Lymphoma 28Lymphoma, Large B-Cell, Diffuse 27Carcinoma, Hepatocellular 27Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, B-Cell 25Brain Neoplasms 25Advanced Solid Tumor 25Myelodysplastic Syndromes 24

Interventions

olaparib 1lutetium Lu 177 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoid Tumor × 90 days × Clear all
NCT04086485 2026-05-22

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
56 enrolled
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡